Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000196776 | SCV000254206 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2022-03-08 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA2 protein function. ClinVar contains an entry for this variant (Variation ID: 216256). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces methionine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 2493 of the BRCA2 protein (p.Met2493Thr). |
| Ambry Genetics | RCV004948210 | SCV005548738 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-08-20 | criteria provided, single submitter | clinical testing | The p.M2493T variant (also known as c.7478T>C), located in coding exon 14 of the BRCA2 gene, results from a T to C substitution at nucleotide position 7478. The methionine at codon 2493 is replaced by threonine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |